Bright Minds Biosciences (DRUG) Q2 2026 earnings — TrendMatrix coverage

Reported EPS

-$0.24

Estimate

-$1.64

Surprise

+85.3%

Score today

5.7/10

Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.

Bright Minds Biosciences (DRUG) reported a narrower loss than forecast — diluted EPS of -$0.24 against the -$1.64 estimate (a 85.3% beat on a still-unprofitable quarter).

TrendMatrix currently rates DRUG Sell at 5.7/10; no pre/post engine snapshot brackets this report.

4 of the last 4 quarters beat the estimate; this quarter's +85.3% surprise compares with a +39.7% four-quarter average. Next scheduled report: 2026-12-22.

This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.

Current price

$77.42

Price target

$145.53

Stop

$72.00

Upside to target

+88.0%

Reward-to-risk

7.9:1

Model outputs from TrendMatrix’s engine as of 2026-08-23 — shown for context, not personalized investment advice.

Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.

Industry

Biotechnology

Market cap

$759.6M

P/E (fwd)

-13.2

52-week range

$38.00–$123.75

Off 52-week high

37.4%

RSI (14)

56

Volume vs avg

0.93×

Score today

5.7/10